CUGRASTOMIG
UNII 8JU4Y2PP36

Substance Identification & Data

This profile provides standardized clinical and technical data for Cugrastomig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 8JU4Y2PP36.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2852680-10-3 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

8JU4Y2PP36

CAS Registry Number

2852680-10-3

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

CUGRASTOMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C206897

National Cancer Institute reference terminology for clinical and research data.

INN ID

12924

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Cugrastomig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Cugrastomig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Cugrastomig

Common Names & Synonyms

H-gamma1 heavy chain anti-LAG3 fused to a scFv anti-PDCD1 (1-716) [ Hgamma1 heavy chain anti-LAG3 Homo sapiens (1-450) [VH (Homo sapiens IGHV4-34*01 (90.6%) -(IGHD) -IGHJ5*02 (93.8%), CDR-IMGT [8.7.14] (26-33.51-57.96-109)) (1-120)-Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, G1v14-1 CH2 A1.3, A1.2, A1 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 L1.3>A (237), L1.2>A (238), G1>A (240)(234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)] -20-mer tetrakis(tetraglycyl-seryl) linker (451-470) -scFvhk anti-PDCD1 humanized and chimeric (471-716) [humanized VH (Homo sapiens IGHV3-23*04 (88.7%) -IGHD -IGHJ6*01 (90.9%) T123>L (583), CDR-IMGT [8.8.11] (496-503.521-528.567-577)) (471-588) -20-mer tetrakis(tetraglycyl-seryl) linker (589-608) -VKAPPA Musmus/Homsap (Mus musculus IGKV14-111*01 (86.3%) -IGKJ5*01 (100%)/Homo sapiens IGKV1-16*01 (80.0%) -IGKJ2*01 (81.8%) Q120>A (708), I126>L (714), CDR-IMGT [6.3.9] (635-640.658-660.697-705)) (609-716)]]; (223-214')-disulfide with L-kappa light chain anti-LAG3 Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV3-11*01 (97.9%) -IGKJ5*01 (91.7%) R123>N (103'), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153'), V101 (191') (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

Immunoglobulin G1 [237-alanine,238-alanine,240-alanine], bispecific, anti-(human lymphocyte activation gene-3 protein) (human-Mus musculus monoclonal AK129 γ1-chain) fusion protein with peptide linker ((GGGGS)4) fusion protein with immunoglobulin anti-(human programmed cell death protein 1) (human-Mus musculus single-chain variable fragment VH-(GGGGS)4-VL), disulfide with human-Mus musculus monoclonal AK129 κ-chain, dimer

cugrastomig [INN]

immunoglobulin IG fused to 2 scFv (H-gamma1-scFvhk_L'-kappa) dimer bisdisulfide, anti-[Homo sapiens LAG3 (lymphocyte activating 3, lymphocyteactivation 3, CD223)] and scFv anti-[Homo sapiens PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], Homo sapiens, humanized and chimeric monoclonal antibody, bispecific, tetravalent

External Clinical & Regulatory Resources

Previous UNII8JTY7VW9J8

Next UNII8JUZ5VA03X